Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Arcadia Biosciences, Inc.

NASDAQ: RKDA · Energy & Transportation · 3 alerts · CIK 1469443

Share price
$0.1936Close, Nov 16
Market cap
$1.17M
Shares outstanding
6.07MLatest SEC cover page
Sector
Energy & Transportation
Industry
Crude Petroleum & Natural GasSIC 1311

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Arcadia Biosciences, Inc. filings on SEC EDGAR ↗

4:14 PM ET 10-Q
Financial Results

Arcadia Biosciences Q3 2026 Results: Net Income $1.75M, Up 105.0% YoY

Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.

Key figure
Net income $1.75M · +105.0% YoY
4:10 PM ET 8-K
Financial Results

Arcadia Biosciences Financial Results

Arcadia Biosciences reported third-quarter 2026 financial results, highlighted by a 24% year-over-year increase in total revenues to $1.6 million. The growth was primarily driven by record quarterly sales for the Zola coconut water brand, which benefited from strong summer promotional programs and expanded distribution.

Term
Q3 2026

“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”

T.J. Schaefer, CEO of Arcadia

“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”

T.J. Schaefer, CEO of Arcadia
3:02 PM ET 8-K
Shareholder Meeting

Arcadia Biosciences Shareholder Meeting

Arcadia Biosciences held its 2026 Annual Meeting of Stockholders where shareholders elected Gregory D. Waller as a Class II director and approved the new 2026 Omnibus Equity Incentive Plan. Stockholders also approved a potential reverse stock split at a ratio between 1-for-2 and 1-for-10, to be implemented at the Board's discretion before June 30, 2027, and ratified executive compensation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.